文献速递类风湿关节炎脊柱关节炎

法国巴黎科钦大学医院在炎症性慢性病日常临床实践中将原研英夫利西单抗系统性转换为生物类似药英夫利西单抗的经验

Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France.
PubMed 文献 · Semin Arthritis Rheum · 2017-10-05

这项前瞻性观察研究在法国巴黎科钦大学医院将260例接受原研英夫利西单抗维持治疗的成人患者系统性转换为生物类似药英夫利西单抗,第三次输注时保留率为85%(221/260),平均随访34周内59例(23%)停药,主要因疗效不佳(n=47,80%),未发生严重不良事件,客观疾病活动参数及英夫利西单抗谷浓度无变化,但脊柱关节炎患者BASDAI显著升高(2.94±2.20 vs 3.18±2.21,P=0.046,转换前 vs 转换后)。

要点

  • 第三次输注时生物类似药英夫利西单抗保留率为85%(221/260)。
  • 平均随访34周内59例(23%)停药,其中47例(80%)因疗效不佳。
  • 脊柱关节炎患者BASDAI在转换后显著升高(2.94±2.20 vs 3.18±2.21,P=0.046)。

核心结论

  • 在真实临床实践环境中系统性转换为生物类似药英夫利西单抗后,未观察到药物谷浓度或客观参数的变化。
  • 仅观察到患者报告结局的变化,提示为归因效应而非药理学差异。

研究设计与样本

  • 前瞻性观察研究,纳入法国巴黎科钦大学医院所有接受原研英夫利西单抗维持治疗的成人患者,系统性转换为生物类似药英夫利西单抗。
  • 共260例患者符合纳入标准,包括31例类风湿关节炎、131例中轴型脊柱关节炎和64例炎症性肠病。
  • 有效性通过第三次输注时生物类似药英夫利西单抗的保留率评估;敏感性分析包括基线至末次访视之间疾病活动参数和英夫利西单抗谷浓度的变化,以及导致停药的 adverse events 发生情况。
  • 探索了末次访视时与生物类似药英夫利西单抗停药相关的因素。

主要发现

  • 第三次生物类似药输注时保留率为85%(221/260例)。
  • 基线至末次访视(平均随访34周)期间,59例(23%)停用生物类似药英夫利西单抗,主要原因为疗效不佳(n=47,80%)。
  • 未发现与生物类似药停药相关的临床或生物学因素。
  • 未发生严重不良事件;未检测到客观疾病活动参数或英夫利西单抗谷浓度的变化。
  • 脊柱关节炎患者BASDAI显著升高(转换前2.94±2.20 vs 转换后3.18±2.21,P=0.046)。

关键数值与推荐

  • 第三次输注时生物类似药英夫利西单抗保留率为85%(221/260例)。
  • 平均随访34周内59例(23%)停药,其中47例(80%)因疗效不佳。
  • 脊柱关节炎患者BASDAI转换前2.94±2.20 vs 转换后3.18±2.21(P=0.046)。
  • 47/59例(80%)患者重新使用原研英夫利西单抗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate effectiveness of systematic switching treatment from innovator infliximab to biosimilar infliximab, and its associated factors. METHODS: In this prospective observational study, all adult patients receiving maintenance therapy with innovator infliximab in Cochin University Hospital were systematically switched to biosimilar infliximab. Effectiveness was assessed by the retention rate of biosimilar infliximab at the time of the third infusion. Sensitivity analyses for effectiveness included changes of disease activity parameters and infliximab trough levels between baseline and the last visit as well as the occurrence of adverse events leading to drug discontinuation. Factors associated with biosimilar infliximab discontinuation at the last visit were explored. RESULTS: A total of 260 patients fulfilled the inclusion criteria, including 31 rheumatoid arthritis (RA), 131 axial spondyloarthritis (axSpA) and 64 inflammatory bowel diseases. The retention rate was 85% (221/260 patients) at the time of the third biosimilar infusion. Between baseline and the last visit (mean follow-up of 34 weeks), 59 patients (23%) discontinued biosimilar infliximab, mainly due to experienced inefficacy (n = 47, 80%). No clinical or biological factors were associated with biosimilar discontinuation. No serious adverse events occurred. No change in objective disease activity parameters or infliximab trough levels was detected. However, a significant increase of BASDAI (2.94 ± 2.20 vs. 3.18 ± 2.21, P = 0.046, before vs. after switch, respectively) was observed in patients with axSpA. Innovator infliximab was re-established in 47/59 patients (80%). CONCLUSION: No changes in drug trough levels or objective parameters were observed after the systematic switch to biosimilar infliximab in a real clinical practice setting. Only changes in patient-reported outcomes were observed, suggesting attribution effects rather than pharmacological differences.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Avouac J, Moltó A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum. 2017. PMID: 29102156. doi:10.1016/j.semarthrit.2017.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。